Product patent regime poses serious challenge to domestic industry unless it invests in R&D

DPCO puts unrealistic ceilings on product prices & profitability & prevents pharma companies in generating investible surpluses

Export effort hampered by procedural hurdles & non tariff barriers imposed abroad

Lowering of tariff protection